Gan & Lee Pharmaceuticals.

This Phase 3 trial will test a new once-daily insulin, GZR33, against the standard insulin degludec (Tresiba) in 350 adults with type 2 diabetes whose blood sugar is not well controlled by oral medications. The main goal is to see how well GZR33 lowers blood sugar over 26 weeks c…

This Phase 3 study tests whether switching to a once-monthly injection of GZR18 can help 500 overweight or obese adults maintain weight loss for an additional 24 weeks. All participants previously completed a year of biweekly GZR18 treatment. The study measures changes in body we…

This early-stage study tests GZR18, an injectable drug for obesity or overweight, in 60 Chinese adults. Researchers want to see how it affects stomach emptying and whether it changes how the body processes digoxin (heart medication), rosuvastatin (cholesterol drug), and warfarin …

This study tests a new insulin drug, GZR4, against another insulin (Insulin Icodec) in 300 adults with type 2 diabetes who already use basal insulin. The goal is to see which one controls blood sugar better and causes fewer side effects like low blood sugar. Participants may also…

This Phase 3 trial compares a new injectable drug, GZR18, to the popular weight-loss medication Wegovy (semaglutide) in 420 adults who are obese or overweight. The main goal is to see how much weight participants lose after 52 weeks of treatment. Researchers will also check for s…

This study checks if a new version of the GZR18 injection works the same as the old version in healthy adult men. About 138 men will get a single shot and have their blood tested over 35 days. The goal is to see if the drug levels in the body are similar, not to treat any disease…

This early-stage study tests a single dose of the drug GZR18 in 32 adults who are overweight or obese, some with mild to severe kidney problems and some with normal kidneys. Researchers want to see how kidney function affects drug levels and safety. The goal is to find the right …